• First Patient Dosed in Phase 2 Trial of eFT508 for Aggressive Non-Hodgkin’s Lymphoma
  • Xynomic Pharma Plans 4 Clinical Trials of Abexinostat for Lymphoma
  • First-line GEM-P Chemo Fails to Improve Response Rates in Peripheral T-cell Lymphomas, Results Show
  • This Is Why I’m Grateful for Cancer
  • Imbruvica-Rituxan Combo Significantly Delays Progression of Rare Type of Lymphoma in Phase 3 Trial
  • Cerdulatinib Shows Promising Phase 2a Trial Results in Blood Cancer Patients, Including NHL
  • Phase 3 Trial to Test Yescarta as Second-line Therapy for DLBCL Patients
  • Phase 2 Data Continues to Support Remetinostat in Easing Itching in Early Stage Mycosis Fungoides
  • Alexo Begins Testing ALX148 Combinations in Phase 1 Trial of NHL, Solid Tumors
  • Upon Hearing Those 3 Words: ‘You Have Cancer’
  • CAR T-cell Therapy JCAR017 Shows Sustained Anticancer Response in Aggressive B-Cell Lymphoma, Trial Update Reports
  • Xalkori Named Breakthrough Therapy for Difficult-to-Treat Rare Lymphoma